Luo Xiaolong, Chen Peng, Wu Alan Chengqing, Pan Guohua, Li Mingyu, Chen Guang, Dong Qian, Cline Gary A, Dornseif Bruce E, Jin Zhezhen
Celgene Corporation, 300 Connell Drive, Berkeley Heights, NJ 07922, United States.
Celgene Corporation, 300 Connell Drive, Berkeley Heights, NJ 07922, United States.
Contemp Clin Trials. 2015 Nov;45(Pt B):239-243. doi: 10.1016/j.cct.2015.09.013. Epub 2015 Sep 24.
Planned and unplanned subgroup analyses of large clinical trials are frequently performed and the results are sometimes difficult to interpret. The source of a nominal significant finding may come from a true signal, variation of the clinical trial outcome or the observed data structure. Quantitative assessment is critical to the interpretation of the totality of the clinical data. In this article we provide a general framework to manage subgroup analyses and to interpret the findings through a set of supplement analyses to planned main (primary and secondary) analyses, as an alternative to the commonly used multiple comparison framework. The proposed approach collectively and coherently utilizes several quantitative methods and enhances the credibility and interpretability of subgroup analyses. A case study is used to illustrate the application of the proposed method.
大型临床试验的计划内和计划外亚组分析经常进行,其结果有时难以解释。名义上显著发现的来源可能来自真实信号、临床试验结果的变异或观察到的数据结构。定量评估对于解释临床数据的整体情况至关重要。在本文中,我们提供了一个通用框架,用于管理亚组分析,并通过一组对计划内主要(主要和次要)分析的补充分析来解释研究结果,作为常用多重比较框架的替代方法。所提出的方法共同且连贯地运用了多种定量方法,增强了亚组分析的可信度和可解释性。通过一个案例研究来说明所提出方法的应用。